Integrase Inks Antiviral Pact with UGARF; Hopes to Ride Coattails of Merck Approval | GenomeWeb
In one of its largest technology licensing deals completed to date, the University of Georgia Research Foundation has granted a license to biopharma company Inhibitex for intellectual property covering a series of HIV integrase inhibitors, hepatitis C polymerase inhibitors, and other antiviral compounds, Integrase and UGARF said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.